We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-11.53%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$842M
AUM Growth
-$295M
Cap. Flow
-$112M
Cap. Flow %
-13.31%
Top 10 Hldgs %
47.05%
Holding
143
New
42
Increased
27
Reduced
21
Closed
50

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$14M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.9M
3
AMRN
Amarin Corp
AMRN
+$9.5M
4
SIBN icon
SI-BONE Inc
SIBN
+$9.49M
5
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$7.51M

Top Sells

Rank Stock Value
1
GRFS
Grifois
GRFS
+$13.5M
2
AGN
Allergan plc
AGN
+$13.3M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$7.52M
4
CNMD icon
CONMED
CNMD
+$5.18M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$4.53M

Sector Composition

Rank Sector Weight
1 Healthcare 34.76%
2 Industrials 1.16%
3 Consumer Staples 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
76
CALL
Corbus Pharmaceuticals
CRBP
$189M
$890K 0.11%
+5,663
New +$957K
BMY.RT
77
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$755K 0.09%
+198,740
New +$655K
SRACU
78
DELISTED
Stable Road Acquisition Corp. Unit
SRACU
$744K 0.09%
74,070
-361,780
-83% -$3.71M
SVRA icon
79
Savara
SVRA
$1.17B
$723K 0.09%
340,868
+53,758
+19% +$147K
AGTC
80
DELISTED
Applied Genetic Technologies Corporation
AGTC
$680K 0.08%
+207,358
New +$1.09M
TPST icon
81
CALL
Tempest Therapeutics
TPST
$19.3M
$676K 0.08%
+656
New +$957K
CRBP icon
82
Corbus Pharmaceuticals
CRBP
$189M
$629K 0.07%
+4,000
New +$676K
AXSM icon
83
CALL
Axsome Therapeutics
AXSM
$11.2B
$588K 0.07%
+10,000
New +$815K
EOLS icon
84
Evolus
EOLS
$536M
$587K 0.07%
141,442
-54,141
-28% -$459K
PBYI icon
85
Puma Biotechnology
PBYI
$459M
$540K 0.06%
+64,000
New +$622K
EOLS icon
86
CALL
Evolus
EOLS
$536M
$531K 0.06%
+128,000
New +$1.08M
CBAY
87
CALL
DELISTED
Cymabay Therapeutics
CBAY
$524K 0.06%
354,000
+27,000
+8% +$45.3K
ABEO icon
88
Abeona Therapeutics
ABEO
$425M
$391K 0.05%
7,454
-2,356
-24% -$157K
TRIL
89
DELISTED
Trillium Therapeutics Inc.
TRIL
$390K 0.05%
+96,487
New +$365K
SRRA
90
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$186K 0.02%
+18,940
New +$248K
ATXS
91
DELISTED
Astria Therapeutics
ATXS
$75K 0.01%
+3,018
New +$93.6K
MAPSW
92
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$12K ﹤0.01%
50,000
– –
ABT icon
93
PUT
Abbott
ABT
$192B
– –
-137,000
Closed -$11.9M
ALKS icon
94
Alkermes
ALKS
$8.44B
– –
-54,000
Closed -$1.1M
APLT
95
DELISTED
Applied Therapeutics
APLT
– –
-21,810
Closed -$595K
BAX icon
96
CALL
Baxter International
BAX
$13.9B
– –
-205,500
Closed -$17.2M
BCRX icon
97
BioCryst Pharmaceuticals
BCRX
$2.71B
– –
-2,179,950
Closed -$7.52M
BYND icon
98
PUT
Beyond Meat
BYND
$214M
– –
-54,000
Closed -$4.08M
CABA icon
99
Cabaletta Bio
CABA
$465M
– –
-154,792
Closed -$2.16M
CGC
100
PUT
Canopy Growth
CGC
$431M
– –
-30,000
Closed -$6.33M
2 3
4
5 6

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q1 2020 Portfolio in Review

As of Q1 2020, Pura Vida Investments held 143 positions worth $842M, down 26% from $1.14B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Pura Vida Investments withdrew a net $112M in Q1 2020, closing 50 positions and reducing 21 holdings. Its most notable exit was Grifois, an estimated $13.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 26% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in AtriCure worth $13.1M.

  • Pura Vida Investments's largest Q1 2020 buy was AtriCure: 388,994 shares worth $13.1M.
  • Pura Vida Investments added most to Alexion Pharmaceuticals in Q1 2020, an estimated $11.9M increase.
  • Pura Vida Investments's biggest Q1 2020 reduction was DexCom, cutting an estimated $4.46M.
  • Pura Vida Investments fully exited Grifois in Q1 2020, selling an estimated $13.5M.
  • Pura Vida Investments's ten largest holdings make up 47% of its $842M portfolio in Q1 2020.
  • Pura Vida Investments opened 42 new positions and closed 50 in Q1 2020.
  • Pura Vida Investments's portfolio value fell 26% quarter-over-quarter to $842M.

Based on Pura Vida Investments's 13F filing for Q1 2020, filed 15 May 2020.